Literature DB >> 22133815

Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy.

K Kern1, K M Schebesch, J Schlaier, E Hansen, G C Feigl, A T Brawanski, M Lange.   

Abstract

Anticonvulsant drugs are frequently given after craniotomy. Phenytoin (PHT) is the most commonly used agent; levetiracetam (LEV) is a new anticonvulsant drug with fewer side effects. To compare the incidence of seizures in patients receiving either prophylactic PHT or LEV perioperatively, 971 patients undergoing a craniotomy were analysed retrospectively during a 2-year period. PHT was used routinely and LEV was administered when PHT was contraindicated. Seizures documented during the first 7 days after craniotomy were considered. A total of 235 patients were treated with an antiepileptic drug: 81 patients received LEV, and 154 patients, PHT. Two patients receiving LEV (2.5%) and seven receiving PHT (4.5%) had a seizure despite this treatment. No patient had a documented side effect or drug interaction. The data show that LEV may be an alternative option in patients with contraindications to PHT.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133815     DOI: 10.1016/j.jocn.2011.07.021

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  14 in total

Review 1.  Levetiracetam for seizure prevention in brain tumor patients: a systematic review.

Authors:  Ziad Ghantous Nasr; Bridget Paravattil; Kyle John Wilby
Journal:  J Neurooncol       Date:  2016-05-11       Impact factor: 4.130

Review 2.  Antiseizure medications in critical care: an update.

Authors:  Baxter Allen; Paul M Vespa
Journal:  Curr Opin Crit Care       Date:  2019-04       Impact factor: 3.687

3.  Seizure outcomes of supratentorial brain tumor resection in pediatric patients.

Authors:  Fadi S Saadeh; Edward F Melamed; Nolan D Rea; Mark D Krieger
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

4.  Levetiracetam versus phenytoin: a comparison of efficacy of seizure prophylaxis and adverse event risk following acute or subacute subdural hematoma diagnosis.

Authors:  Julia Anne Elisabeth Radic; Sherry H-Y Chou; Rose Du; Jong Woo Lee
Journal:  Neurocrit Care       Date:  2014-10       Impact factor: 3.210

Review 5.  Efficacy and safety of prophylactic levetiracetam in supratentorial brain tumour surgery: a systematic review and meta-analysis.

Authors:  Chryssa Pourzitaki; Georgia Tsaousi; Eirini Apostolidou; Konstantinos Karakoulas; Dimitrios Kouvelas; Ekaterini Amaniti
Journal:  Br J Clin Pharmacol       Date:  2016-04-24       Impact factor: 4.335

6.  Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review.

Authors:  Young Jin Lee; Tackeun Kim; So Hyun Bae; Young-Hoon Kim; Jung Ho Han; Chang-Ho Yun; Chae-Yong Kim
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

Review 7.  Cardiovascular adverse effects of phenytoin.

Authors:  B Guldiken; J Rémi; Soheyl Noachtar
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

8.  Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis.

Authors:  Taolin Fang; Eduard Valdes; Jennifer A Frontera
Journal:  Neurocrit Care       Date:  2021-07-20       Impact factor: 3.210

9.  Fosphenytoin for seizure prevention in childhood coma in Africa: a randomized clinical trial.

Authors:  Samson A Gwer; Richard I Idro; Gregory Fegan; Eddie M Chengo; Ayub Mpoya; Esther Kivaya; Jane Crawley; Simon N Muchohi; Michael N Kihara; Bernhards R Ogutu; Fenella J Kirkham; Charles R Newton
Journal:  J Crit Care       Date:  2013-10-14       Impact factor: 3.425

Review 10.  The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications.

Authors:  Ryosuke Hanaya; Kazunori Arita
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-03-02       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.